H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $36 from $33 and keeps a Buy rating on the shares. The firm says privosegtor may be priced above $100,000 per treatment if successfully developed and approved.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology
- Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating
- Oculis initiated with a Buy at Needham
- Nvidia reportedly stops H20 AI chip output for China: Morning Buzz
- Oculis price target raised to $33 from $32 at H.C. Wainwright